Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide continuous subcutaneous infusion versus Revlimid oral capsules pharmacokinetic crossover study in healthy adult men
NL-OMON50544Completed
- Sponsor
- Starton Therapeutics
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of lenalidomide in multiple myeloma (MM) (2 arms), sponsored by Starton Therapeutics. Primary endpoint: Pharmacokinetics of continuous subcutaneous infusion versus oral capsules. Started Mar 2022; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON50544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50544.